These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 24285175)

  • 1. Prompt use of neuraminidase inhibitors improves survival of children severely ill with flu.
    McCarthy M
    BMJ; 2013 Nov; 347():f7127. PubMed ID: 24285175
    [No Abstract]   [Full Text] [Related]  

  • 2. The truth about Tamiflu? Neuraminidase inhibitors in pandemic A/H1N1 flu.
    Weber JT; Nicoll A; Bridges CB; Ciancio BC
    BMJ; 2010 Jan; 340():c130. PubMed ID: 20071425
    [No Abstract]   [Full Text] [Related]  

  • 3. [Neuraminidase inhibitors - lessons from the swine flu].
    Markun S
    Praxis (Bern 1994); 2013 May; 102(11):687-8. PubMed ID: 23692909
    [No Abstract]   [Full Text] [Related]  

  • 4. Statistical and methodological concerns about the beneficial effect of neuraminidase inhibitors on mortality.
    Wolkewitz M; Schumacher M
    Lancet Respir Med; 2014 Jul; 2(7):e8-9. PubMed ID: 24948434
    [No Abstract]   [Full Text] [Related]  

  • 5. Statistical and methodological concerns about the beneficial effect of neuraminidase inhibitors on mortality.
    Leonardi-Bee J; Venkatesan S; Muthuri SG; Nguyen-Van-Tam JS; Myles PR;
    Lancet Respir Med; 2014 Jul; 2(7):e10-2. PubMed ID: 24948433
    [No Abstract]   [Full Text] [Related]  

  • 6. Statistical and methodological concerns about the beneficial effect of neuraminidase inhibitors on mortality.
    Jones M; Del Mar C; Hama R
    Lancet Respir Med; 2014 Jul; 2(7):e9-e10. PubMed ID: 24948431
    [No Abstract]   [Full Text] [Related]  

  • 7. Statistical and methodological concerns about the beneficial effect of neuraminidase inhibitors on mortality.
    Antes G; Meerpohl JJ
    Lancet Respir Med; 2014 Jul; 2(7):e10. PubMed ID: 24948429
    [No Abstract]   [Full Text] [Related]  

  • 8. Neuraminidase inhibitors for critically ill children with influenza.
    Louie JK; Yang S; Samuel MC; Uyeki TM; Schechter R
    Pediatrics; 2013 Dec; 132(6):e1539-45. PubMed ID: 24276847
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiviral treatment for patients hospitalized with 2009 pandemic influenza A (H1N1).
    Uyeki T
    N Engl J Med; 2009 Dec; 361(23):e110. PubMed ID: 19923564
    [No Abstract]   [Full Text] [Related]  

  • 10. Editor in chief's reply to Nguyen-Van-Tam.
    Godlee F
    BMJ; 2014 Apr; 348():g2951. PubMed ID: 24780322
    [No Abstract]   [Full Text] [Related]  

  • 11. Emergence of a multidrug-resistant pandemic influenza A (H1N1) virus.
    van der Vries E; Stelma FF; Boucher CA
    N Engl J Med; 2010 Sep; 363(14):1381-2. PubMed ID: 20879894
    [No Abstract]   [Full Text] [Related]  

  • 12. Oseltamivir resistance: what does it mean clinically?
    Baum SG
    Clin Infect Dis; 2009 Dec; 49(12):1836-7. PubMed ID: 19911972
    [No Abstract]   [Full Text] [Related]  

  • 13. The beneficial effects of neuraminidase inhibitor drug therapy on severe patient outcomes during the 2009-2010 influenza A virus subtype H1N1 pandemic.
    Aoki FY; Hayden FG
    J Infect Dis; 2013 Feb; 207(4):547-9. PubMed ID: 23204176
    [No Abstract]   [Full Text] [Related]  

  • 14. Neuraminidase inhibitors--the story behind the Cochrane review.
    Doshi P
    BMJ; 2009 Dec; 339():b5164. PubMed ID: 19995813
    [No Abstract]   [Full Text] [Related]  

  • 15. Global transmission of oseltamivir-resistant influenza.
    Moscona A
    N Engl J Med; 2009 Mar; 360(10):953-6. PubMed ID: 19258250
    [No Abstract]   [Full Text] [Related]  

  • 16. [Pandemic (H1N1) 2009 in children].
    Mitamura K
    Nihon Rinsho; 2010 Sep; 68(9):1643-9. PubMed ID: 20845741
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oseltamivir boosts 2009 H1N1 virus infectivity in vitro.
    Lin X; Zhou J; Zhang Y; Wu J; Zhang F; Li Z; Zhang Y; Bi S; Shu Y; Wang Y
    Biochem Biophys Res Commun; 2009 Dec; 390(4):1305-8. PubMed ID: 19879239
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influenza--the case for combination therapy.
    Krystal MR; Meanwell NA
    Curr Opin Investig Drugs; 2009 Aug; 10(8):746-9. PubMed ID: 19649919
    [No Abstract]   [Full Text] [Related]  

  • 19. Clinical effectiveness of oseltamivir and zanamivir for treatment of influenza A virus subtype H1N1 with the H274Y mutation: a Japanese, multicenter study of the 2007-2008 and 2008-2009 influenza seasons.
    Kawai N; Ikematsu H; Hirotsu N; Maeda T; Kawashima T; Tanaka O; Yamauchi S; Kawamura K; Matsuura S; Nishimura M; Iwaki N; Kashiwagi S
    Clin Infect Dis; 2009 Dec; 49(12):1828-35. PubMed ID: 19911968
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emergence of oseltamivir-resistant pandemic H1N1 virus during prophylaxis.
    Baz M; Abed Y; Papenburg J; Bouhy X; Hamelin ME; Boivin G
    N Engl J Med; 2009 Dec; 361(23):2296-7. PubMed ID: 19907034
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.